ProCE Banner Activity

CheckMate 032: Nivolumab ± Ipilimumab With Promising Activity in Recurrent SCLC

Slideset Download
Conference Coverage
Results of phase I study of nivolumab with or without ipilimumab in patients with SCLC and progression on prior therapy.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation